<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711668</url>
  </required_header>
  <id_info>
    <org_study_id>B.30.2.ATA.0.01.00/308</org_study_id>
    <nct_id>NCT04711668</nct_id>
  </id_info>
  <brief_title>Effect of Introperative Ketamine and Lidocaine Infusion on Postoperative Opioid Consumption in Posterior Spinal Fusion Surgery</brief_title>
  <official_title>The Effect of Introperative Ketamine and Lidocaine Infusion on Postoperative Opioid Consumption in Posterior Spinal Fusion Surgery - Double-Blind Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ataturk University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ataturk University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The primary aim of this study was to investigate the effect of ketamine and&#xD;
      lidocaine on postoperative opioid consumption in posterior spinal fusion surgery.&#xD;
&#xD;
      Materials and Methods: Ethics committee approval was received from our faculty. Seventy-five&#xD;
      cases between the ages of 18-65, who have an ASA (American Society of Anesthesiologists) risk&#xD;
      classification I-II-III in the preanesthetic evaluation, planned to be operated by the&#xD;
      Neurosurgery clinic for lumbar posterior spinal fusion surgery under elective conditions have&#xD;
      been included in the study after the informed volunteer consent form was read and approved.&#xD;
&#xD;
      The patients were randomly divided into 3 groups using the closed envelope method. The&#xD;
      ketamine group (Group K) (n = 25), the lidocaine group (Group L) (n = 25) and the placebo&#xD;
      group (Group P) (n = 25). Propofol, rocuronium and fentanyl i.v. done. In group K, 0.5 mg /&#xD;
      kg i.v. ketamine bolus and 0.25 mg / kg / hr i.v. ketamine infusion was administered. In&#xD;
      group L, 1.5 mg / kg i.v. lidocaine bolus and 1.5 mg / kg / hr i.v. lidocaine infusion was&#xD;
      administered. In group P, i.v. saline (in the same volume and duration) was applied.&#xD;
      Maintenance of anesthesia was provided by propofol and remifentanil infusion. The propofol&#xD;
      and remifentanil doses were adjusted according to the BIS monitoring and the increase or&#xD;
      decrease in basal blood pressure and heart rate values of 20% or more. The BIS value was kept&#xD;
      between 40-60. At the end of surgery, infusions were closed. After extubation, the patients&#xD;
      were taken to the recovery room. Patient controlled analgesia (PCA) prepared with fentanyl&#xD;
      was applied to the patients for postoperative analgesia. The PCA device was attached for 24&#xD;
      hours postoperatively.&#xD;
&#xD;
      Postoperative 0-4 hours, 4-8 hours, 8-24 hours and total fentanyl consumption of the patients&#xD;
      were evaluated. Pain scores were measured at 1, 2, 4, 8, 12 and 24 hours in the postoperative&#xD;
      recovery room. Intraoperative propofol and remifentanil consumption was recorded. Tramadol 1&#xD;
      mg / kg i.v. as rescue analgesia (in patients with VAS pain score of 4 and above) done.&#xD;
      Possible side effects due to opioid, ketamine and lidocaine were followed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2019</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative opioid consumption</measure>
    <time_frame>postoperative 0-24 hours</time_frame>
    <description>postoperative PCA wit fentanyl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative pain score</measure>
    <time_frame>postoperative 0-24 hours</time_frame>
    <description>pain score is visual analogue scala</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Spine Fusion</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group Ketamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg / kg i.v. ketamine bolus at induction and 0.25 mg / kg / hr i.v. ketamine infusion intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Lidokain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5 mg / kg i.v. lidocaine bolus at induction and 1.5 mg / kg / hr i.v. lidocaine infusion intraoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>i.v. saline (in the same volume and duration like group ketamine/lidokain)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>intraoperative ketamine bolus and infusion</description>
    <arm_group_label>Group Ketamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocain</intervention_name>
    <description>intraoperative lidocain bolus and infusion</description>
    <arm_group_label>Group Lidokain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>intraoperative saline bolus and infusion</description>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  between the ages of 18-65, who have an ASA (American Society of Anesthesiologists)&#xD;
             risk classification I-II-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous spinal surgery, Morbid obesity (BMI&gt; 35 kg / m2), Lidocaine, ketamine or&#xD;
             opioid allergy. Severe cardiac or pulmonary disease, Liver or kidney dysfunction&#xD;
             Poorly controlled hypertension, Substance abuse, Chronic opioid use, Pregnancy,&#xD;
             Psychiatric disorder, Cognitive impairment History of stroke, head injury, and&#xD;
             intracranial mass or bleeding and patients who did not want to participate in the&#xD;
             study were excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Atatürk University</name>
      <address>
        <city>Erzurum</city>
        <zip>25100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 13, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ataturk University</investigator_affiliation>
    <investigator_full_name>Vedat Öztürk</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

